Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

ATRIAL FIBRILLATION - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Atrial Fibrillation in US$ Million by the following segments: Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics. Annual estimates and forecasts are provided for the period 2006 through 2015. Also, the report provides market revenues for Atrial Fibrillation therapies for the years 2006 through 2015. The report profiles 34 companies including many key and niche players such as AtriCure, Inc., Baxter International, Inc., Becton, Dickinson & Company, Biosense Webster, Inc., Boston Scientific Corp., Cardiome Pharma Corp., C.R. Bard, Inc., Cardima, Inc., Endosense SA, Medtronic, Inc., Sanofi-Aventis, Sorin SpA, Spectrasonics, Inc., St. Jude Medical, Inc., and Zimmer Holdings, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6194
Price : $3950
Companies : 34
Pages : 301
Date : August 2010
Market Data Tables : 100

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  ATRIAL FIBRILLATION (Complete Report) Pages : 301   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$295
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY73$3000
  1. INDUSTRY OVERVIEW.....II-16 $950  
   Atrial fibrillation: A Prelude.....II-1
Market Outlook.....II-1
1$100
   The Market Opportunity.....II-2
Table 1: Population Growth (60+ age group) over the Period 2009-2013¬ (includes corresponding Graph/Chart).....II-2
1$300
   Side-Effects and Ineffectiveness Mar Current AF Drug Therapy Option.....II-3
Non-Pharmacotherapy to Exhibit Strong Growth.....II-3
1$100
   Table 2: Global Atrial Fibrillation Market (2007): Annual Atrial Fibrillation Procedures by Region/ Country - US, Europe and Rest of World (includes corresponding Graph/Chart).....II-4
Ablation Catheters to Bolster Market Growth for AF Devices.....II-4
Increased Popularity of Ablation Catheters Drive Product Developments.....II-4
1$300
   Clinical Trials and Technology Enhancements Propel AF Ablation Market.....II-5
Convenience and Safety Brings Novel Anticoagulants to the Forefront.....II-5
Diagnostic EP Catheters Poised for Robust Growth.....II-5
Mapping Features in Diagnostic EP Catheters Contribute to Growth.....II-5
1$100
   Balloon Catheters: Most Effective Treatment for Paroxysmal AF.....II-6
New Technologies in Ablation.....II-6
1$100
  2. TREATMENT OF ATRIAL FIBRILLATION.....II-716 $1450  
   Treatment Objectives for Atrial Fibrillation.....II-7
Existing Treatment Protocols: Pharmacological and Interventional Approach.....II-7
1$100
   Pharmacological Treatment.....II-8
Rate and Rhythm Control.....II-8
Rate Control.....II-8
1$100
   Popular Drugs Used for Rate Control.....II-9
Rhythm Control.....II-9
Popular Drugs Used for Rhythm Control.....II-9
1$100
   List of Different Types of Antiarrhythmic Drugs.....II-10
Stroke Prevention through Drugs.....II-10
1$100
   Anticoagulation.....II-111$100
   Cardioversion.....II-12
Chemical Cardioversion.....II-12
Electrical Cardioversion.....II-12
1$100
   Table 3: Global Atrial Fibrillation Market (2007): Percentage Response Rate of Most Effective Therapy for Treatment of Atrial Fibrillation by Drugs - Diltiazem (Cardizem), Electrical Cardioversion, Amiodarone (Cordarone), Propranolol, Ibutilide (Corvert) and Other (includes corresponding Graph/Chart).....II-131$300
   Select Anti-Arrhythmic drugs.....II-14
Multaq® (dronedarone).....II-14
Amiodarone.....II-14
1$100
   Digoxin (Lanoxin).....II-151$100
   Non-Pharmacological Treatment.....II-16
Ablate and Pace Technique.....II-16
Left Atrial Appendage Closure – Alternative to Anticoagulation.....II-16
Catheter Ablation.....II-16
1$100
   Techniques of Catheter Ablation.....II-171$100
   Patient Selection.....II-18
Results of AF Ablation.....II-18
Complications.....II-18
2$200
   Post-Ablation Considerations.....II-20
Pulmonary Vein Isolation.....II-20
Cox Maze.....II-20
1$100
   Minimally-Invasive Maze Techniques.....II-21
Standard Surgical Ablation.....II-21
HIFU Surgical Ablation.....II-21
1$100
   Other Recent Approaches to Ablation.....II-22
1$100
  3. ELECTROPHYSIOLOGY ABLATION – A REGIONAL PERSPECTIVE.....II-235 $950  
   Europe.....II-23
Physician’s Confidence and New Product Launches Fuel Growth.....II-23
Inorganic Growth to Keep Alive European Electrophysiology Market.....II-23
Technological Sophistication to Drive Growth in European EP Ablation Catheters
  Market.....II-23
1$100
   Cost Cutting Measures Pull Back European EP Ablation Catheters Market.....II-24
Technological Breakthroughs Augur Growth in European Cardiac Rhythm
  Management.....II-24
United States.....II-24
Key Statistical Findings.....II-24
Table 4: US Atrial Fibrillation Prevalence for the Period 2010-2050 (includes corresponding Graph/Chart).....II-24
1$300
   Table 5: US Atrial Fibrillation Market Occurrence by Age and Gender: 2006 (includes corresponding Graph/Chart).....II-25

Table 6: US Atrial Fibrillation Market (2006): Percentage Utilization of Medical Service by Patients with AF (includes corresponding Graph/Chart).....II-25
1$300
   Table 7: US Atrial Fibrillation Market (2006): Average Annual Direct-Per-Patient Costs Incurred by Patients with AF (includes corresponding Graph/Chart).....II-26

Table 8: US Atrial Fibrillation Therapeutic Market (2007): Percentage Breakdown of Revenues by Category - Amiodarone, Sotalol, Propafenone, Fiecainide, and Others (includes corresponding Graph/Chart).....II-26

Table 9: US Healthcare Spending (in US$ trillion): 2008 and 2017.....II-26

Table 10: US ICD Market Share (2010): Percentage Breakdown of Market Share by Players - Medtronic, Boston Scientific, St. Jude Medical and Others (includes corresponding Graph/Chart).....II-26
1$300
   US Electrophysiology Ablation Catheters Market: An Overview.....II-27
Atrial Fibrillation Procedures on Growth Trajectory.....II-27
Manual Steering Procedures Score over Robotic and Remote Magnetic Guidance
  Systems.....II-27
China.....II-27
Canada.....II-27
1$100
  4. ATRIAL FIBRILLATION - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS.....II-2812 $950  
   Introduction.....II-28
What is Atrial Fibrillation?.....II-28
History of AF.....II-28
Risk Factors.....II-28
Controllable Risk Factors.....II-28
1$100
   Non-Controllable Risk Factors.....II-29
Steps to Reduce Risk Factors and Treat Underlying Reasons.....II-29
1$100
   Preventive Measures.....II-30
Causes of Atrial Fibrillation.....II-30
Symptoms of Atrial Fibrillation.....II-30
1$100
   Consequences of Atrial Fibrillation.....II-31
Morbidity and Mortality Consequences.....II-31
AF Significantly Impacts Quality of Life.....II-31
Impact on Healthcare System.....II-31
Patterns of Atrial Fibrillation.....II-31
First Detected AF.....II-31
Paroxysmal Atrial Fibrillation.....II-31
1$100
   Persistent Atrial Fibrillation.....II-32
Chronic or Permanent Atrial Fibrillation.....II-32
Postoperative Atrial Fibrillation.....II-32
Classification of Atrial Fibrillation.....II-32
Lone Atrial Fibrillation (LAF).....II-32
Non-valvular AF.....II-32
Secondary AF.....II-32
1$100
   Identification of Atrial Fibrillation.....II-33
Diagnosis or Evaluation of AF.....II-33
Minimal Evaluation Methods.....II-33
Routine Blood Diagnosis.....II-33
1$100
   Electrocardiogram.....II-34
Tilt-Table Test.....II-34
Physical Examination and History.....II-34
Extended Evaluation Methods.....II-34
Event Recording.....II-34
Echocardiography.....II-34
Trans-esophageal Echocardiogram.....II-34
1$100
   Chest X-Ray.....II-35
Electrophysiology Study.....II-35
Exercise-Stress Testing.....II-35
1$100
   Ambulatory Holter Monitoring.....II-36
Cardiac Mapping.....II-36
1$100
   Effects of Atrial Fibrillation.....II-37
Progressive Atria Fibrosis.....II-37
Thromboembolism.....II-37
1$100
   Research on Atrial Fibrillation.....II-38
2$200
  5. CLINICAL TRIALS.....II-4010 $950  
   St. Jude Announces IRASE AF Clinical Trial to Evaluate Cardiac Ablation Catheter System
  for Treating AF.....II-40
Biosense Webster Supports Landmark Global CABANA Clinical Trial for Atrial
  Fibrillation.....II-40
1$100
   Cardiome Pharma Announces Completion of European Comparator Study.....II-41
Mayo Clinic Receives Grant to Study Treatment for Atrial Fibrillation.....II-41
1$100
   Medtronic Completes STOP-AF Trial of Medtronic Arctic Front® CryoAblation Catheter
  System.....II-42
The Mount Sinai Medical Center Uses Atrial Ablation Catheter of CardioFocus.....II-42
US Cardiologists Carry Out First 3D Imaging of Complex Cardiac Anatomy.....II-42
Warfarin Therapy Found Effective for Atrial Fibrillation.....II-42
1$100
   ABLATE Clinical Trial of AtriCure for Evaluation of Isolator SynergyTM Bipolar Ablation
  System.....II-43
1$100
   Ablation Frontiers’ Atrial Fibrillation Cardiac Ablation Technology Evaluated.....II-44
Montreal Heart Institute Organizes Global Clinical Trial.....II-44
1$100
   deCODE Genetics Highlights Clinical Utility of deCODE AFTM.....II-451$100
   Boehringer Ingelheim Announces Enrollment for RE-LY Trial.....II-461$100
   RF Ablation Generator and Catheter Proves to be Successful in Atrial
  Fibrillation.....II-47
ATI-2042 Proves Successful in Atrial Fibrillation.....II-47
1$100
   NaviStar® ThermoCool Catheter Proves Better Treatment Alternative than AAD
  Therapy.....II-48
2$200
  6. PRODUCT APPROVALS.....II-505 $395  
   St. Jude Medical's Anthem RF CRT-P and Accent RF Pacemaker Receive FDA
  Approval.....II-50
Sorin Group Acquires Regulatory Approval to Market Pacemakers in Japan.....II-50
1$100
   NaviStar Catheter Receives FDA Approval for Atrial Fibrillation.....II-51
Multaq Receives EU Approval for Atrial Fibrillation.....II-51
Multaq Receives Approval from Health Canada for Atrial Fibrillation.....II-51
1$100
   Sanofi-aventis Receives FDA Approval for Multaq 400 mg Tablets.....II-52
St. Jude Medical's Current Accel and AnalyST Accel ICDs Receive CE Mark.....II-52
Biosense Webster Manufactured Devices Receive FDA Approval.....II-52
1$100
   Cardima Obtains CE Mark Approval for Surgical Ablation Probe with Stabilization
  Sheath.....II-53
St. Jude Receives CE Mark Approval for SJM ConfirmTM ICM.....II-53
1$100
   CV Therapeutics Manufactured Ranexa Obtains FDA Approval.....II-54
1$100
  7. RECENT INDUSTRY ACTIVITY.....II-556 $495  
   dosense and Biotronik Sign Global Distribution Agreement.....II-55
Merck Acquires Commercial Rights for Betrixaban.....II-55
Erasmus University Medical Centre and CLT Israel Sign Joint Venture Agreement.....II-55
1$100
   Gilead Sciences to Take Over CV Therapeutics.....II-56
BMS, Teijin Pharma and Nissan Chemical Industries form Worldwide Collaboration.....II-56
Medtronic Acquires Ablation Frontiers.....II-56
1$100
   Merck Signs Collaboration Agreement with Cardiome.....II-57
Royal Philips Collaborates with Bard to Co-Develop Clinical Tools for
  Arrhythmias.....II-57
1$100
   Medtronic Acquires CryoCath Technologies.....II-58
Heritage Pharma and Ipca Laboratories Enter into Strategic Alliance.....II-58
Nissan Chemical to Seek Overseas Licensee for Atrial Fibrillation Drug.....II-58
Boston Scientific Acquires CryoCor.....II-58
1$100
   St. Jude Signs Merger Agreement with MediGuide.....II-59
St. Jude Medical Acquires EP MedSystems.....II-59
Cardima Signs Marketing Contract with On-X Life Technologies.....II-59
1$100
   Angiotech Pharmaceuticals Signs Licensing Agreement with Symphony Medical.....II-60
AtriCure Acquires Frigitronics CCS-200 Product Range from Cooper Surgical.....II-60
1$100
  8. PRODUCT LAUNCHES.....II-615 $395  
   Sorin Introduces Implant of Advanced Cardiac Resynchronization Therapy
  Defibrillator.....II-61
Sanofi-aventis Launches Multaq in the US.....II-61
Medtronic Launches Insertable Cardiac Monitor in US.....II-61
1$100
   St. Jude Medical Launches Medical Devices for Heart Rhythm Disorders.....II-621$100
   eCardio Diagnostics Launches AFISTM Informatics Solution.....II-63
BIOTRONIK Unveils Lumax 540 Devices for Cardiac Rhythm Management in the US.....II-63
1$100
   CardioNet Launches Improved CardioNet AF Management Program.....II-64
LifeWatch Launches First Commercial LifeWatch Atrial Fibrillation Patient Care
  Program.....II-64
1$100
   CryoCath Technologies Launches Arctic Front in Belgium, Spain and Italy.....II-65
ATS Medical Introduces ATS CryoMaze Clamp for Surgical Ablation.....II-65
1$100
  9. FOCUS ON SELECT MAJOR PLAYERS.....II-666 $495  
   AtriCure, Inc. (US).....II-66
Baxter International, Inc. (US).....II-66
Becton, Dickinson & Company (US).....II-66
1$100
   Biosense Webster, Inc. (US).....II-67
Boston Scientific Corp. (US).....II-67
1$100
   Cardiome Pharma Corp. (Canada).....II-68
C.R. Bard, Inc. (US).....II-68
Cardima, Inc. (US).....II-68
1$100
   Endosense SA (Switzerland).....II-69
Medtronic, Inc. (US).....II-69
1$100
   Sanofi-Aventis (France).....II-70
Sorin SpA (Italy).....II-70
Spectrasonics, Inc. (US).....II-70
1$100
   St. Jude Medical, Inc. (US).....II-71
Zimmer Holdings, Inc. (US).....II-71
1$100
  10. GLOBAL MARKET PERSPECTIVE.....II-72   
   Table 11: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Segment - Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-721$300
   Table 12: World 10-Year Perspective for Atrial Fibrillation by Segment - Percentage Breakdown of Dollar Sales by Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories and Diagnostics for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-73

Table 13: Atrial Fibrillation Therapies Worldwide: Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-73
1$300
III. COMPETITIVE LANDSCAPE 216$995
  
Total Companies Profiled: 34 (including Divisions/Subsidiaries - 41)

Region/Country                 Players


The United States                 26   
Canada                             3
Japan                              2
Europe                             9
     France                        2
     Germany                       2
     The United Kingdom            1
     Italy                         1
     Rest of Europe                3
Asia-Pacific (Excluding Japan)     1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign